19-04-06 08:37
Age: 2 yrs

BY: TOWNER, COLIN J.; ZUJKOWSKI, STEVE

The pharmaceutical industry is an area where there is significant activity around EPC and understanding how best to apply the technology to improve efficiency and reduce losses. Cap Gemini Ernst & Young (CGE&Y) in collaboration with the Auto-ID Center has developed a business case for the adoption of Auto-ID in the pharmaceutical industry. This case, based on CGE&Y’s extensive experience with the world’s leading pharmaceutical companies, distributors and hospitals, reflects the opportunities available to these companies from Auto-ID applications. This white paper identifies not only the opportunities available within the supply chain, it also includes benefits within the drug development and clinical trials process, as well as improvements to patient safety and effects on gray market activities. Companies who read this document should note that the benefits of Auto-ID do not always require multi-company collaboration, many are realizable within the company’s internal operations and direct control. Cap Gemini Ernst & Young (www.cgey.com) is one of the world’s largest providers of Consulting, Technology and Outsourcing services with offices around the world. CGE&Y provides a full set of services to help clients transform their operations and technologies as well as operates business processes and information technologies for many of the world’s leading companies.

<- Back to: Publications